Comparison of combined intralesional injection of glucantime and interferon gamma with intralesional glucantime alone in the treatment of cutaneous leishmaniasis
Not Applicable
- Conditions
- Cutaneous Leishmaniasis.Protozoal diseasesB50,B51,B5
- Registration Number
- IRCT2015012420740N2
- Lead Sponsor
- Mashhad University of Medical Sciences, Vice Chancellor for Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 90
Inclusion Criteria
Inclusion criterias: Positive smear or biopsy of the lesion in terms of Amastigotes; Not sensitivity to glucantime; The patient who has indications of topical treatment based on state protocol; Less than one year past from onset of the illness; No treatment is received in at least 2 months; Not pregnant and not lactating; The patient is willing to participate in the study. exclusion criterias: No have regular visit; Secondary infection of the lesion based on clinical features and judging therapist; Use of other medications during the study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The rate of healing. Timepoint: Once a week up to 12 weeks after treatment. Method of measurement: Outcomes based on the percent reduction of induration: full healing (100% healing), significant healing (75%> reduce induration), relatively healing (50-75% reduce induration), low healing (25-50% reduce induration), no response (25%< reduce induration).
- Secondary Outcome Measures
Name Time Method Treatment effects. Timepoint: Once a week up to 12 weeks after treatment. Method of measurement: Local or systemic clinical reactions cause of using drugs.